Effects of teriparatide versus percutaneous vertebroplasty on pain relief, quality of life and cost-effectiveness in postmenopausal females with acute osteoporotic vertebral compression fracture: A prospective cohort study.

Ma Y, Wu X, Xiao X, Ma Y, Feng L, Yan W, Chen J, Yang D

Bone13 Nov 2019Cited by 32 (Europe PMC)

PMID31733423DOI10.1016/j.bone.2019.115154PepBankPUB-31733423

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In postmenopausal women with acute vertebral fractures, health quality improved similarly with teriparatide and vertebroplasty plus alendronate.
In plain wordsIn postmenopausal women with vertebral fractures, teriparatide and vertebroplasty plus alendronate were linked to similar improvements in health quality.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHealth quality at first and third months
Study
n = 60
Comparator
Percutaneous vertebroplasty plus alendronate
Outcome group
Quality of life · Whole body
Studied dose
20 μg once daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Both treatments with TPTD and PVP significantly and similarly improved the patients' health quality, with reduced visual analogue and ODI scores at the end of the first and third months.
2 context sentences(design, population, supporting numbers)
Summary · context
This investigation represents a real-world prospective cohort study, where 60 postmenopausal women (≥55 years old) with acute OVCFs were equally assigned to a TPTD conservative group or PVP (plus alendronate) group based on the patient's choice.
Summary · context
TPTD (20 μg, s.c., once daily) or alendronate (70 mg, p.o., once weekly) were administrated together with 0.6 mg Caltrate and 500 iu Vitamin D3 per day.
Report a problemFND-3173342301
02HumanObservational studyEfficacy outcome
In postmenopausal women with acute vertebral fractures, pain scores declined similarly with teriparatide and vertebroplasty plus alendronate.
In plain wordsIn postmenopausal women with vertebral fractures, teriparatide and vertebroplasty plus alendronate were linked to similar declines in pain scores.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVAS pain scores at first and third months
Study
n = 60
Comparator
Percutaneous vertebroplasty plus alendronate
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg once daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Both treatments with TPTD and PVP significantly and similarly improved the patients' health quality, with reduced visual analogue and ODI scores at the end of the first and third months.
2 context sentences(design, population, supporting numbers)
Summary · context
This investigation represents a real-world prospective cohort study, where 60 postmenopausal women (≥55 years old) with acute OVCFs were equally assigned to a TPTD conservative group or PVP (plus alendronate) group based on the patient's choice.
Summary · context
TPTD (20 μg, s.c., once daily) or alendronate (70 mg, p.o., once weekly) were administrated together with 0.6 mg Caltrate and 500 iu Vitamin D3 per day.
Report a problemFND-3173342302
03HumanObservational studyEfficacy outcome
In postmenopausal women with acute vertebral fractures, disability scores declined similarly with teriparatide and vertebroplasty plus alendronate.
In plain wordsIn postmenopausal women with vertebral fractures, teriparatide and vertebroplasty plus alendronate were linked to similar declines in disability scores.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOswestry Disability Index at first and third months
Study
n = 60
Comparator
Percutaneous vertebroplasty plus alendronate
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg once daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Both treatments with TPTD and PVP significantly and similarly improved the patients' health quality, with reduced visual analogue and ODI scores at the end of the first and third months.
2 context sentences(design, population, supporting numbers)
Summary · context
This investigation represents a real-world prospective cohort study, where 60 postmenopausal women (≥55 years old) with acute OVCFs were equally assigned to a TPTD conservative group or PVP (plus alendronate) group based on the patient's choice.
Summary · context
TPTD (20 μg, s.c., once daily) or alendronate (70 mg, p.o., once weekly) were administrated together with 0.6 mg Caltrate and 500 iu Vitamin D3 per day.
Report a problemFND-3173342303
04HumanObservational studyEfficacy outcome
In postmenopausal women with acute vertebral fractures, teriparatide provided less pain reduction than vertebroplasty plus alendronate at 1 week.
In plain wordsIn postmenopausal women with vertebral fractures, teriparatide was linked to less pain reduction than vertebroplasty plus alendronate at 1 week.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePain reduction at 1 week
Study
n = 60
Comparator
Percutaneous vertebroplasty plus alendronate
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg once daily · subcutaneousAs given in this study (human).
Source sentences
Summary
PVP was more effective in reducing pain at the early time point (1 week, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This investigation represents a real-world prospective cohort study, where 60 postmenopausal women (≥55 years old) with acute OVCFs were equally assigned to a TPTD conservative group or PVP (plus alendronate) group based on the patient's choice.
Summary · context
TPTD (20 μg, s.c., once daily) or alendronate (70 mg, p.o., once weekly) were administrated together with 0.6 mg Caltrate and 500 iu Vitamin D3 per day.
Report a problemFND-3173342304
05HumanObservational studyOther
In postmenopausal women with acute vertebral fractures, teriparatide treatment cost less per patient than vertebroplasty plus alendronate.
In plain wordsIn postmenopausal women with vertebral fractures, teriparatide was linked to lower treatment costs than vertebroplasty plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseDirect medical cost
Study
n = 60
Comparator
Percutaneous vertebroplasty plus alendronate
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
20 μg once daily · subcutaneousAs given in this study (human).
Measurements
Treatment cost
21868.61 RMB per capita
teriparatide
Treatment cost
33265.95 RMB per capita
vertebroplasty
Source sentences
Summary
The cost of TPTD treatment was 21,868.61 ± 167.05 RMB per capita, while the cost for PVP treatment was 33,265.95 ± 1491.11 RMB per capita (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This investigation represents a real-world prospective cohort study, where 60 postmenopausal women (≥55 years old) with acute OVCFs were equally assigned to a TPTD conservative group or PVP (plus alendronate) group based on the patient's choice.
Summary · context
TPTD (20 μg, s.c., once daily) or alendronate (70 mg, p.o., once weekly) were administrated together with 0.6 mg Caltrate and 500 iu Vitamin D3 per day.
Report a problemFND-3173342307
06HumanObservational studyEfficacy outcome
In postmenopausal women with acute vertebral fractures receiving teriparatide, 24 of 27 rescanned patients showed bone healing on MRI.
In plain wordsIn postmenopausal women with acute vertebral fractures receiving teriparatide, 24 of 27 rescanned patients showed bone healing.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableMRI bone healing
Study
n = 27
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg once daily · subcutaneousAs given in this study (human).
Measurements
Patients with bone healing
24 patients
27 rescanned teriparatide patients
Source sentences
Summary
24 of 27 patients who were rescanned with magnetic resonance imaging in the TPTD group showed bone healing.
2 context sentences(design, population, supporting numbers)
Summary · context
This investigation represents a real-world prospective cohort study, where 60 postmenopausal women (≥55 years old) with acute OVCFs were equally assigned to a TPTD conservative group or PVP (plus alendronate) group based on the patient's choice.
Summary · context
TPTD (20 μg, s.c., once daily) or alendronate (70 mg, p.o., once weekly) were administrated together with 0.6 mg Caltrate and 500 iu Vitamin D3 per day.
Report a problemFND-3173342305
07HumanObservational studyEfficacy outcome
In postmenopausal women with acute vertebral fractures, mid-vertebral height did not increase with teriparatide, unlike vertebroplasty.
In plain wordsIn postmenopausal women with acute vertebral fractures, vertebral height did not increase with teriparatide, unlike vertebroplasty.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMid-vertebral height
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg once daily · subcutaneousAs given in this study (human).
Source sentences
Summary
The mid-vertebral height was increased by PVP (p < 0.05) but not by TPTD.
2 context sentences(design, population, supporting numbers)
Summary · context
This investigation represents a real-world prospective cohort study, where 60 postmenopausal women (≥55 years old) with acute OVCFs were equally assigned to a TPTD conservative group or PVP (plus alendronate) group based on the patient's choice.
Summary · context
TPTD (20 μg, s.c., once daily) or alendronate (70 mg, p.o., once weekly) were administrated together with 0.6 mg Caltrate and 500 iu Vitamin D3 per day.
Report a problemFND-3173342306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.